| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/23/2002 | CN1332731A Substituted benzimidazoles and their prep. and use |
| 01/23/2002 | CN1332727A 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives |
| 01/23/2002 | CN1332626A Inhalation system |
| 01/23/2002 | CN1332168A 3-substituted pyrido-[4',3':4,5] thieno-[2,3-d] pyrimidine derivatives, their prep. and use |
| 01/23/2002 | CN1332154A Carbamate compound and its prep. |
| 01/23/2002 | CN1332010A Chinese medicine prepn for treating psychosis |
| 01/23/2002 | CN1331994A Chinese medicine for treating diabetic neural lesion |
| 01/23/2002 | CN1331978A Application of sowthistle in preparing tobacco toxin resisting medicine |
| 01/23/2002 | CN1078208C Pyrrolyl tetrahydrobenzoquinoxaline diones, their preparation and use as glutamate receptor antagonists |
| 01/23/2002 | CN1078071C Use of pharmaceutical compositions |
| 01/22/2002 | US6340758 Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents |
| 01/22/2002 | US6340709 Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing |
| 01/22/2002 | US6340704 Cell differentiation inducing amide derivatives, their production and use |
| 01/22/2002 | US6340700 2-(iminomethyl) amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same |
| 01/22/2002 | US6340694 Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors |
| 01/22/2002 | US6340685 Antiinflammatory agents |
| 01/22/2002 | US6340681 Useful as analgesics in mammals |
| 01/22/2002 | US6340680 Oxazinoquinolones useful for the treatment of viral infections |
| 01/22/2002 | US6340673 Administering at or near a site of a tumor of tumorigenic disease a herpes simplex virus vector lacking an expressible .gamma..sub.1 34.5 gene, whereby the growth of tumor is suppressed |
| 01/22/2002 | US6340668 Administering bone morphogenetic protein-11 (bmp-11) to neuronal cells effective to promote the survival of cells |
| 01/22/2002 | US6340476 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 01/22/2002 | CA2093794C 1'-aminospiro¬isoquinoline-4(1h),3-pyrrolidine|-1,2',3,5'-(2h)-tetrones and analogs thereof useful as aldose reductase inhibitors |
| 01/22/2002 | CA2043709C Antimigraine alkoxypyrimidine derivatives |
| 01/22/2002 | CA2027876C Use of substituted imidazoles |
| 01/20/2002 | CA2358356A1 Pharmaceutical composition containing citalopram |
| 01/17/2002 | WO2002004949A2 Reagents and methods for identification of binding agents |
| 01/17/2002 | WO2002004642A1 Novel polypeptide and dna thereof |
| 01/17/2002 | WO2002004641A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/17/2002 | WO2002004640A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/17/2002 | WO2002004639A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/17/2002 | WO2002004625A1 α-SYNUCLEIN BINDING PROTEIN |
| 01/17/2002 | WO2002004624A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/17/2002 | WO2002004612A2 Drug metabolizing enzymes |
| 01/17/2002 | WO2002004520A2 Transporters and ion channels |
| 01/17/2002 | WO2002004517A1 A putative g-protein coupled receptor for gamma butyric acid (gab9) |
| 01/17/2002 | WO2002004513A2 Down syndrome critical region 1-like 1 proteins |
| 01/17/2002 | WO2002004509A2 Gene expression, genome alteration and reporter expression in myofibroblasts and myofibroblast-like cells |
| 01/17/2002 | WO2002004490A2 Lipid metabolism molecules |
| 01/17/2002 | WO2002004482A1 Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| 01/17/2002 | WO2002004474A1 Adenosine compound and pharmaceutical composition containing the same |
| 01/17/2002 | WO2002004472A1 Novel compounds and methods |
| 01/17/2002 | WO2002004457A1 Azepino[4,5-b]pyrano[3,2-e]indoles |
| 01/17/2002 | WO2002004456A1 SUBSTITUTED 2,3,7,8,9,10,11,12-OCTAHYDROAZEPINO[4,5-b]PYRANO[3,2-e]INDOLES |
| 01/17/2002 | WO2002004455A2 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof |
| 01/17/2002 | WO2002004442A2 Azabicyclic compounds as inhibitors of nicotinic cholinergic receptors |
| 01/17/2002 | WO2002004433A2 Melanin concentrating hormone receptor ligands |
| 01/17/2002 | WO2002004409A2 Tetrahydrobenzothiazole analogues as neuroprotective agents |
| 01/17/2002 | WO2002004029A1 Olfactory neuron cultures and method of making and using the same |
| 01/17/2002 | WO2002004025A1 Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| 01/17/2002 | WO2002004019A2 Use of strains of the parapox ovis virus against organ fibrosis |
| 01/17/2002 | WO2002004016A1 Enteric preparations containing physiologically active peptides |
| 01/17/2002 | WO2002004002A2 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
| 01/17/2002 | WO2002003988A2 Use of substituted indole compounds for treating neuropeptide y-related conditions |
| 01/17/2002 | WO2002003975A2 Combinations of ssri and estrogenic agents |
| 01/17/2002 | WO2002003972A2 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds |
| 01/17/2002 | WO2002003911A2 Prevention and treatment of alzheimer's disease |
| 01/17/2002 | WO2002003848A2 Method for opening the blood-brain barrier |
| 01/17/2002 | WO2002003815A2 Composition for the treatment of migraine |
| 01/17/2002 | WO2002003813A1 Use of dammarane-type triterpenoid saponins |
| 01/17/2002 | WO2001081309A3 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol |
| 01/17/2002 | WO2001068138A3 Intradermal-penetration agents for topical local anesthetic administration |
| 01/17/2002 | WO2001062726A3 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 01/17/2002 | WO2001060826A3 SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| 01/17/2002 | WO2001054681A8 Composition for treatment of stress |
| 01/17/2002 | WO2001047922A3 Azaindoles |
| 01/17/2002 | WO2001047543A3 Activation and inhibition of the immune system |
| 01/17/2002 | WO2001044448A3 Human oxidoreductase proteins |
| 01/17/2002 | WO2001041782A3 Method for administering a cytokine to the central nervous system and the lymphatic system |
| 01/17/2002 | WO2001035948A3 Neurophilin ligands for treating ocular conditions |
| 01/17/2002 | WO2001034769A3 24 human secreted proteins |
| 01/17/2002 | WO2001034178A3 Methods and compositions for treatment of traumatic brain injury |
| 01/17/2002 | WO2001022972A3 Immunostimulatory nucleic acids |
| 01/17/2002 | WO2001019817A3 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| 01/17/2002 | WO2001016293A3 Dna encoding the human serine protease t |
| 01/17/2002 | WO2001012598A3 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 01/17/2002 | WO2001012171A3 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| 01/17/2002 | WO2001007471A3 Cell cycle and proliferation proteins |
| 01/17/2002 | WO2001001973A3 Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 01/17/2002 | WO2000078971A3 Atp binding cassette transporter protein abc1 popypeptides |
| 01/17/2002 | WO2000078953A3 Human transport proteins |
| 01/17/2002 | WO2000078952A3 Human rna metabolism proteins (rmep) |
| 01/17/2002 | WO2000061129A3 S-hydroxynefazodone |
| 01/17/2002 | WO2000025798A8 Treatment of parkinson's disease with oligonucleotides |
| 01/17/2002 | US20020007075 Neurological disorders including physically damaged nerves and neurodegenerative diseases, and for treating alopecia and promoting hair growth; Alzheimer's, Parkinson's disease; amyotrophic lateral sclerosis |
| 01/17/2002 | US20020007074 Imidazole derivatives having affinity for alpha2 receptors |
| 01/17/2002 | US20020007066 For treatment/prevention of infection of herpes simplex virus, varicella zoster virus, human cytomegalovirus, or epstein-Barr virus; enzyme inhibitors |
| 01/17/2002 | US20020007065 Cyclopentanone dihydropyridine compounds useful as potassium channel openers |
| 01/17/2002 | US20020007064 For prevention of psychotic disorders such as schizophrenia and other central nervous system diseases |
| 01/17/2002 | US20020006965 Methods and compositions for treating depression and other disorders using optically pure (-)-bupropion |
| 01/17/2002 | US20020006964 Eating disorders; psychological disorders |
| 01/17/2002 | US20020006963 Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds |
| 01/17/2002 | US20020006959 Therapy for reduced nervous cell metabolism |
| 01/17/2002 | US20020006957 Method for the synthesis of compounds of formula I and their uses thereof |
| 01/17/2002 | US20020006951 Solid-state form of celecoxib having enhanced bioavailability |
| 01/17/2002 | US20020006948 Central nervous system disorders; antiinflammatory agents |
| 01/17/2002 | US20020006947 Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof |
| 01/17/2002 | US20020006946 Obesity, antidiabetic agents, cardiovascular disorders |
| 01/17/2002 | US20020006941 p53 inhibitors and therapeutic use of the same |
| 01/17/2002 | US20020006934 Phenyl-substituted imidazopyridines |
| 01/17/2002 | US20020006932 Central nervous system disorders; heeadaches, antiinflammatory agents |